Weiyun Zhang

Weiyun Zhang

Auto-generated profile, based on publicly available information

Weiyun Zhang

General Hospital of Southern Theatre Command of PLA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Gene
Verified
Journal Article
Closed access
BXBin Xiao
Bin Xiao
WZWeiyun Zhang
Weiyun Zhang
LCLidan Chen
Lidan Chen
JHJianfeng Hang
Jianfeng Hang
LWLizhi Wang
Lizhi Wang
LLLinhai Li
Linhai Li

11 April 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BXBin Xiao
Bin Xiao
LCLidan Chen
Lidan Chen
YKYongli Ke
Yongli Ke
JHJianfeng Hang
Jianfeng Hang
LCLing Cao
Ling Cao
LLLinhai Li
Linhai Li
Robust and precise molecular prognostic predictors for luminal breast cancer are required. This study aimed to identify key methylation sites in luminal breast cancer, as well as precise molecular tools for predicting prognosis. We compared methylation levels of normal and luminal breast cancer samples from The Cancer Genome Atlas dataset. The relationships among differentially methylated sites, corresponding mRNA expression levels and prognosis were further analysed. Differentially expressed genes in normal and cancerous samples were analysed, followed by the identification of prognostic signature genes. Samples were divided into low- and high-risk groups based on the signature genes. Prognoses of low- and high-risk groups were compared. The Gene Expression Omnibus dataset were used to validate signature genes for prognosis prediction. Prognosis of low- and high-risk groups in Luminal A and Luminal B samples from the TCGA and the Metabric cohort dataset were analyzed. We also analysed the correlation between clinical features of low- and high- risk groups as well as their differences in gene expression. Fourteen methylation sites were considered to be related to luminal breast cancer prognosis because their methylation levels, mRNA expression and prognoses were closely related to each other. The methylation level of SOSTDC1 was used to divide samples into hypo- and hyper-methylation groups. We also identified an mRNA signature, comprising eight transcripts, ESCO2, PACSIN1, CDCA2, PIGR, PTN, RGMA, KLK4 and CENPA, which was used to divide samples into low- and high-risk groups. The low-risk group showed significantly better prognosis than the high-risk group. A correlation analysis revealed that the risk score was an independent prognostic factor. Low- and high- risk groups significantly correlated with the survival ratio in Luminal A samples, but not in Luminal B samples on the basis of the TCGA and the Metabric cohort dataset. Further functional annotation demonstrated that the differentially expressed genes were mainly involved in cell cycle and cancer progression. We identified several key methylation sites and an mRNA signature for predicting luminal breast cancer prognosis. The signature exhibited effective and precise prediction of prognosis and may serve as a prognostic and diagnostic marker for luminal breast cancer.

19 March 2019 in Molecular Biology Reports
Verified
Journal Article
Open access
PDF file
BXBin Xiao
Bin Xiao
JHJianfeng Hang
Jianfeng Hang
TLTing Lei
Ting Lei
YHYongyin He
Yongyin He
ZKZhenzhan Kuang
Zhenzhan Kuang
LLLinhai Li
Linhai Li
Few prognostic indicators with differential expression have been reported among the differing ER statuses. We aimed to screen important breast cancer prognostic genes related to ER status and to construct an efficient prognostic prediction system. mRNA expression profiles were downloaded from TCGA and GSE70947 dataset. Two hundred seventy-one overlapping differentially expressed genes (DEGs) between the ER− and ER+ breast cancer samples were identified. Among the 271 DEGs, 109 prognostically relevant mRNAs were screened. mRNAs such as RASEF, ITM2C, CPEB2, ESR1, ANXA9, and VASN correlated strongly with breast cancer prognosis. Three modules, which contained 28, 9 and 8 enriched DEGs, were obtained from the network, and the DEGs in these modules were enriched in response to hormone stimulus, epithelial cell development, and host cell entry. Using bayes discriminant analysis, 48 signature genes were screened. We constructed a prognostic prediction system using the 48 signature genes and validated this system as relatively accurate and reliable. The DEGs might be closely associated with the prognosis in patients with breast cancer. We validated the effectiveness of our prognostic prediction system by GEO database. Therefore, this system might be a useful tool for preliminary screening and validation of potential prognosis indicators for ER+ breast cancer derived from mechanistic research.

21 April 2016 in Oncotarget
Verified
Journal Article
Open access
LLLinhai Li
Linhai Li
LCLidan Chen
Lidan Chen
JLJun Li
Jun Li
WZWeiyun Zhang
Weiyun Zhang
YLYang Liao
Yang Liao
ZSZhaohui Sun
Zhaohui Sun
Correlational study on mitochondrial DNA mutations as potential risk factors in breast cancer

20 July 2017 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
QLQiao Liao
Qiao Liao
ZSZhengang Shan
Zhengang Shan
WMWang Min
Wang Min
JHJieting Huang
Jieting Huang
RXRu Xu
Ru Xu
XRXia Rong
Xia Rong